Inupadenant hydrochloride is under clinical development by ITeos Therapeutics and currently in Phase II for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Head And Neck Cancer Squamous Cell Carcinoma have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Inupadenant hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Inupadenant hydrochloride overview
EOS-850 is under development for the treatment of solid tumors, triple-negative breast cancer, checkpoint inhibitor-refractory melanoma and in a patient with metastatic hormone, head and neck cancer squamous cell carcinoma, non-small cell lung cancer, endometrial cancer and chemotherapy resistant prostate cancer. The drug candidate is a small molecule that acts by targeting adenosine receptor A2A. It is administered through oral route.
ITeos Therapeutics overview
iTeos Therapeutics is a clinical-stage biopharmaceutical company. It discovers and develops immuno-oncology drugs for cancer. The company’s major pipeline products are EOS-448, EOS-984, dostarlimab, iberdomide, pembrolizumab, CD96 drug candidates. Its products are used to treat various cancers like advanced malignancies, relapsed refractory multiple myeloma. The drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations. Its service includes to carries out clinical trials for inupadenant, an A2A receptor antagonist, as a treatment for solid tumors in monotherapy. It has operational presence in the US; and Belgium. iTeos Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Inupadenant hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.